Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Research & Development (2021 - 2026)

MoonLake Immunotherapeutics' Research & Development history spans 6 years, with the latest figure at $54.5 million for Q1 2026.

  • Quarterly Research & Development rose 49.52% to $54.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $220.9 million through Mar 2026, up 62.18% year-over-year, with the annual reading at $202.9 million for FY2025, 79.89% up from the prior year.
  • Research & Development came in at $54.5 million for Q1 2026, down from $56.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $60.6 million in Q3 2025 to a low of $7.4 million in Q1 2023.
  • The 5-year median for Research & Development is $13.0 million (2024), against an average of $26.1 million.
  • The largest YoY upside for Research & Development was 1247.88% in 2022 against a maximum downside of 68.0% in 2022.
  • MoonLake Immunotherapeutics' Research & Development stood at $11.4 million in 2022, then fell by 28.77% to $8.1 million in 2023, then soared by 398.39% to $40.4 million in 2024, then surged by 38.77% to $56.0 million in 2025, then dropped by 2.66% to $54.5 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Research & Development are $54.5 million (Q1 2026), $56.0 million (Q4 2025), and $60.6 million (Q3 2025).